Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 5, 2007, Pages 738-748

  Jacob, Dietmar A ^a   Bahra, Marcus ^a   Langrehr, Jan M ^a   Boas Knoop, Sabine ^a   Stefaniak, Robert ^a   Davis, John ^b   Schumacher, Guido ^a   Lippert, Steffen ^a   Neumann, Ulf P ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

3 aminobenzamide; Apoptosis; Gemcitabine; Pancreatic cancer; PARP inhibitor

Indexed keywords

3 AMINOBENZAMIDE; CASPASE 8; GEMCITABINE; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING;

EID: 34247236605     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04496.x     Document Type: Article

References (32)

1. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64: 191-206.
2. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Semin. Oncol. 2002; 29: 25-35.
3. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002; 87: 161-7.
4. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403-13.
5. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996; 7: 593-600.
6. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85: 1261-8.
7. Bohmig M, Rosewicz S. [Pancreatic carcinoma]. Z. Gastroenterol. 2004; 42: 261-8.
8. Soldani C, Scovassi AI. Poly (ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002; 7: 321-8.
9. Newton CJ, Bilko D, Tichomirowa M, Renner U, Stalla GK. The role of poly (adenosine 5′-diphosphate-ribose) polymerase in the response of pituitary tumor cells to reactive oxygen species. Endocrinology 2005; 146: 1119-27.
10. Chatterjee PK, Chatterjee BE, Pedersen H et al. 5-Aminoisoquinolinone reduces renal injury and dysfunction caused by experimental ischemia/reperfusion. Kidney Int. 2004; 65: 499-509.
11. Kelland LR, Tonkin KS. The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts. Radiother. Oncol. 1989; 15: 363-9.
12. Pan QC, Guo HY. The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide. J. Antibiot. (Tokyo) 1989; 42: 1860-8.
13. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly (ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res. 2002; 45: 73-85.
14. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002; 54: 375-429.
15. Petrou C, Mourelatos D, Mioglou E, Dozi-Vassiliades J, Catsoulacos P. Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide on genotoxicity, antitumor activity, and NAD levels in human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. Teratog. Carcinog. Mutagen. 1990; 10: 321-31.
16. Jacob D, Davis J, Zhu H et al. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin. Cancer Res. 2004; 10: 3535-41.
17. Smith S. The world according to PARP. Trends Biochem. Sci. 2001; 26: 174-9.
18. Wayman N, McDonald MC, Thompson AS, Threadgill MD, Thiemermann C. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5′-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur. J. Pharmacol. 2001; 430: 93-100.
19. Di Paola R, Genovese T, Caputi AP, Threadgill M, Thiemermann C, Cuzzocrea S. Beneficial effects of 5-aminoisoquinolinone, a novel, potent, water-soluble, inhibitor of poly (ADP-ribose) polymerase, in a rat model of splanchnic artery occlusion and reperfusion. Eur. J. Pharmacol. 2004; 492: 203-10.
20. Cuzzocrea S, Mazzon E, Di Paola R et al. 5-Aminoisoquinolinone reduces colon injury by experimental colitis. Naunyn Schmiedebergs Arch. Pharmacol. 2004; 370: 464-73.
21. Khandoga A, Biberthaler P, Enders G, Krombach F. 5-Aminoisoquinolinone, a novel inhibitor of poly (adenosine disphosphate-ribose) polymerase, reduces microvascular liver injury but not mortality rate after hepatic ischemia-reperfusion. Crit. Care Med. 2004; 32: 472-7.
22. Cuzzocrea S, McDonald MC, Mazzon E et al. Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase, in a rodent model of lung injury. Biochem. Pharmacol. 2002; 63: 293-304.
23. Dubner D, del Rosario Perez M, Michelin S et al. Pharmacological inhibition of DNA repair enzymes differentially modulates telomerase activity and apoptosis in two human leukaemia cell lines. Int. J. Radiat. Biol. 2004; 80: 593-605.
24. Tsujiuchi T, Tsutsumi M, Denda A et al. Possible involvement of poly ADP-ribosylation in phenobarbital promotion of rat hepatocarcinogenesis. Carcinogenesis 1990; 11: 1783-7.
25. Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther. 2005; 12: 109-15.
26. Bruns CJ, Koehl GE, Guba M et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin. Cancer Res. 2004; 10: 2109-19.
27. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000; 6: 1936-48.
28. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 2002; 1: 989-97.
29. De Blasio A, Messina C, Santulli A et al. Differentiative pathway activated by 3-aminobenzamide, an inhibitor of PARP, in human osteosarcoma MG-63 cells. FEBS Lett. 2005; 579: 615-20.
30. Jijon HB, Churchill T, Malfair D et al. Inhibition of poly (ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000; 279: G641-51.
31. McDonald MC, Mota-Filipe H, Wright JA et al. Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br. J. Pharmacol. 2000; 130: 843-50.
32. Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl Cancer Inst. 2004; 96: 56-67.